Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 14/20 | 1.00 |
| ▸ | IMPDH1 | P20839 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27571122 | 0.84 | IMPDH2 (0.71) | IMPDH2IMPDH1MEN1KMT2ANPC1 | |
| SCHEMBL6488727 | 0.80 | IMPDH2 (1.00) | IMPDH2IMPDH1 | |
| SCHEMBL27561207 | 0.80 | IMPDH2 (0.67) | IMPDH2IMPDH1MEN1KMT2ANPC1 | |
| SCHEMBL28985219 | 0.80 | KMT2A (0.67) | IMPDH2IMPDH1MEN1KMT2ANPC1 | |
| SCHEMBL27542606 | 0.79 | IMPDH2 (0.64) | IMPDH2IMPDH1NPC1KDM4EPKM | |
| SCHEMBL27561214 | 0.79 | IMPDH2 (0.64) | IMPDH2IMPDH1MEN1KMT2ANPC1 | |
| SCHEMBL1474014 | 0.78 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6484655 | 0.78 | IMPDH2 (0.64) | IMPDH2IMPDH1MEN1KMT2ANPC1 | |
| SCHEMBL20620242 | 0.76 | IMPDH2 (0.61) | IMPDH2IMPDH1MEN1KMT2ANPC1 | |
| SCHEMBL7552277 | 0.75 | IMPDH2 (0.60) | IMPDH2IMPDH1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867299-B2 | Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-20020052513-A1 | Oxamide IMPDH inhibitors | HOFFMANN-LA ROCHE INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1127883-A2 | Oxamides as IMPDH inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052513-A1 | Oxamide IMPDH inhibitors | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885IMPDH1 1/4885MEN1 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.